Search
Does the patient with myelofibrosis feel better through Pacritinib?
Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.
Read moreEHA reaffirms commitment to hematology's future with new brand identity
The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.
Read moreEHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials
EHA has responded to the EMA’s call for comments on the reflection paper on February 15.
Read moreScam alert
Beware of unauthorized or fraudulent hotel and registration booking agencies. INTERPLAN AG is the official housing bureau for the EHA2025 Congress.
Read moreAbout us
The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.
Read morePractical information
Timelines:Application deadline: September 24, 2024 (15:00 CEST)
Notification of awards: December 2024
When & where do the meetings take place?Workshop 1:
Date: April 22-26, 2025
Venue: Cambridge, UK
CBTH session and EHA Congress:
Date: June 11-15, 2025
Venue: TBC
Workshop 2:
Date:…